Generic drug companies have successfully challenged two key Novo Nordisk patents related to the tablet formulation of semaglutide, a blockbuster drug for diabetes (Rybelsus) and weight loss (Wegovy). The European Patent Office’s Boards of Appeal revoked patents EP 2 827 845 and EP 2 827 885, which protected semaglutide’s oral composition. Novo Nordisk maintains that other patents in its portfolio continue to protect the drug.
We are pleased that we have successfully represented Hexal in this case. This text is a summary of an article published by JUVE Patent. The full text of the article is available here.
